#None #DelveInsight #Osteoarthritis #Hyaluronic Acid

Osteoarthritis Market Outlook: 2025-2034

Osteoarthritis (OA) is a chronic joint condition characterized by the gradual degradation of cartilage and other joint tissues. This degenerative disease primarily affects older adults, with its prevalence rising sharply as individuals age. DelveInsight's recent analysis reveals that the osteoarthritis market is set for significant growth during the forecast period from 2025 to 2034, driven by increasing healthcare expenditure and the development of novel treatment options.

In 2024, approximately 97 million cases of diagnosed osteoarthritis were recorded across the seven major markets (7MM), and this number is projected to increase dramatically in the coming decade. The lifetime risk for developing symptomatic knee osteoarthritis is estimated to be around 45-46%, while the risk for hip osteoarthritis stands at 25%. It is evident that there is a growing need for effective treatments given these statistics.

Traditionally, treatments for osteoarthritis involved the use of injectable steroids and hyaluronic acid (HA) into the affected joints. Although these injections have been a common solution, they have sparked debates over efficacy and treatment protocols. Historically, patients required multiple injections, sometimes up to five, to achieve relief. Recent advancements have led to the approval of several FDA-sanctioned HA products that have reduced this requirement to only one or three injections. These products not only provide relief for an extended duration of up to 26 weeks post-injection but also promise to cut down long-term healthcare costs.

Several FDA-approved HA injections, including SUPARTZ, ORTHOVISC, and GEL-ONE, have proven to enhance mobility and alleviate pain. Additionally, ZILRETTA, a unique extended-release treatment for knee osteoarthritis, has emerged as a leading option since its approval by the FDA in 2017.

Moreover, several novel treatments are making waves. JOYCLU, a joint product from Ono Pharmaceutical and Seikagaku Corporation, synergistically combines HA with diclofenac, an anti-inflammatory agent. Meanwhile, AMZ001, a topical gel containing 3.06% diclofenac, has gained traction after showing positive results in a Phase II/III study.

As reflected in DelveInsight's latest report, the market for osteoarthritis treatments is projected to grow from approximately USD 19 billion in 2024, showcasing a robust compound annual growth rate (CAGR) as it confronts evolving treatment paradigms. Opioids currently hold the largest share of this therapeutic market, close to USD 9.4 billion in the US alone.

Additionally, the ongoing rise in demand for innovative therapies is also contributing to market growth. Emerging therapies include novel drug classes such as TRPV1 receptor agonists, and stem cell therapies. Such therapies might not only offer symptomatic relief but could also slow down disease progression.

One notable candidate is ZILOSUL from Paradigm Biopharmaceuticals, which received Fast Track Designation from the FDA in April 2022 for the treatment of osteoarthritis. The support of strong clinical data and ongoing regulatory approvals suggests a hopeful outlook for new drugs entering the market.

The increasing prevalence of osteoarthritis, coupled with advancements in treatment options, underscores a shift towards better management and care for patients suffering from this chronic condition. DelveInsight's comprehensive report, titled Osteoarthritis Market Insight, Epidemiology, and Market Forecast – 2034, promises deep dives into country-specific treatment guidelines and patient demographics, paving the way for strategic development in the osteoarthritis therapeutic landscape.

As the market continues to evolve from 2025 to 2034, it will be exciting to see how these emerging therapies will reshape the standards of care for osteoarthritis and the potential for economic growth within the healthcare sector. Stakeholders and market players are encouraged to stay abreast of developments in this dynamic market to leverage new opportunities and provide improved patient outcomes.